Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE)

详细信息    查看全文

• 作者：Inaam B. Hassan (1) (2)
  Jorgen Kristensen (2)
  Hussain Alizadeh (2)
  Roos Bernsen (3)
  
• 关键词：Adults-acute lymphoblastic leukemia ; Therapy ; Outcome ; Survival ; United Arab Emirates
• 刊名：Medical Oncology
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：30
• 期：2
• 全文大小：369KB
• 参考文献：1. Hoelzer D, Thiel E, Ludwig WD, et al. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group. Leukemia. 1993;7(2):S130-.
  2. G?kbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14(6):1307-5. CrossRef
  3. Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-01. CrossRef
  4. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104(10):3028-7. CrossRef
  5. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: mRC UKALL XII/ECOG E2993 ECOG. Blood. 2005;106(12):3760-. CrossRef
  6. Fielding AK. Current therapeutic strategies in adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2011;25(6):1255-9. CrossRef
  7. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025-7.
  8. Chessells JM, Hall E, Prentice HG, et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12(4):463-3. CrossRef
  9. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10?M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001;15(2):208-6. CrossRef
  10. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863-1. CrossRef
  11. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075-6. CrossRef
  12. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). B Blood. 1992;80(12):2983-0.
  13. Wetzler M, Dodge RK, Mrózek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93(11):3983-3.
  14. Pullarkat V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563-2. CrossRef
  15. Mitchell CD, Richards SM, Kinsey SE, et al. On behalf of the medical research council Childhood Leukemia Working Group. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia:results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129:734-5. CrossRef
  16. Schrappe M, Zimmerman M, Moricke A, et al. Dexamethasone in induction can eliminate one-third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomised trial in 3655 patients (trial AIEOP BFM ALL 2000). Blood. 2008;112: Abstr 7.
  17. Vrooman LM, Neuberg DS, Stevenson KE, et al. Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: results from DFCI-ALL consortium protocol 00-1. Blood (ASH Annual Meeting Abstracts). 2009;114: Abstr 321.
  18. Zheng C, Liu X, Wu J, et al. Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia? Am J Hematol. 2010;85(10):817-. CrossRef
  19. Igarashi S, Manabe A, Ohara A, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children’s Cancer Study Group L95-4 protocol. J Clin Oncol. 2005;23:6489-8. CrossRef
  20. Bertrand Y, Suciu S, Benoit Y, et al. Dexamethasone (DEX)(6?mg/sm/d) and prednisolone (PRED)(60?mg/sm/d) in induction therapy of childhood ALL are equally effective: results of the 2nd interim analysis of EORTC trial 58951. Blood (ASH Annual Meeting Abstracts). 2008; 112: Abstract 8.
  21. Labar B, Suciu S, Willemze R, et al. EORTC leukemia group. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica. 2010;95(9):1489-5. CrossRef
  22. Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547-1.
  23. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43(11):5601-.
  24. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-2. CrossRef
  25. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-1. Blood. 2001;97(5):1211-. CrossRef
  26. Duval M, Suciu S, Ferster A, et al. Comparison of / Escherichia coli–asparaginase with / Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer Children’s Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-. CrossRef
  27. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161-. CrossRef
  28. Hallbook H, Gustafsson G, Smedmyr B, et al. Treatment outcome of young adult and children >10?years of age with acute lymphoblastic leukemia in Sweden. Cancer. 2006;107(7):1551-1. CrossRef
  29. Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, Schmitt C, Piguet C, Stephan JL, Lejars O, Debre M, Jonveaux P, Cayuela JM, Chevret S, Leverger G, Baruchel A, FRALLE group. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer. 2009;13(9):14. CrossRef
  30. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-0. CrossRef
  31. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48:254-1. CrossRef
  32. Stock W, La M, Sanford B. et al; Children’s Cancer Group; Cancer and Leukemia Group B studies. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646-4. CrossRef
  33. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105(9):3434-1. CrossRef
  34. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Blood. 2007;109(8):3189-7. CrossRef
  35. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136-5. CrossRef
  36. Griffin TC, Shuster JJ, Buchanan GR, Murphy SB, Camitta BM, Amylon MD. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2000;14(5):792-. CrossRef
  37. Cetin M. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2003;44(3):489-5. CrossRef
  
• 作者单位：Inaam B. Hassan (1) (2)
  Jorgen Kristensen (2)
  Hussain Alizadeh (2)
  Roos Bernsen (3)
  
  1. Department of Internal Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates
  2. Department of Oncology, Tawam Hospital, Al Ain, United Arab Emirates
  3. Department of Community Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
  

文摘

This retrospective data analysis examined the outcome of 99 acute lymphoblastic leukemia (ALL) patients treated at Tawam Hospital between January 2000 and December 2009. Sixteen patients were treated before June 2002, and 83 patients were treated from June 2002. A modified form of UKALL XII/ECOG E2993 with pulsed dexamethasone in induction phase one (modified UKALL) was the main therapy from June 2002 (71/83). The median age was 28?years. Fifty-eight percent had pre-B ALL where 36?% of them were Philadelphia chromosome-positive (Ph+). Overall, complete remission (CR) rate was 86.7?% which was significantly inferior for patients with white blood cell count 30-00?×?109/l (p?=?0.009), therapy before June 2002 (p?=?0.02), pregnancy (p?=?0.005), CNS leukemia (p?=?0.028), and unknown karyotype (p?=?0.004). With a median follow-up of 11.8?months (0.49-26?months), the estimated overall survival (OS) and event-free survival (EFS) at 3?years were 50.6 and 28.7?%, respectively. OS and EFS were significantly inferior for patients not in CR after induction, age >20?years, Ph+, unknown karyotype and therapy before June 2002. In addition, CR, OS and EFS were significantly superior (p?=?0.004, p?<?0.001 and p?=?0.001, respectively) for therapy with our modified UKALL protocol compared to Tawam protocol (main therapy before June 2002). In conclusion, the outcome of treatment for ALL at our institute is encouraging with significant improvement in the outcome of older adolescents and young adults when using high-intensity chemotherapy. This suggests that such an approach is feasible in developing countries in spite of some limitations including lack of stem cell transplantation service.